ESG Data

Human Capital

Reporting period: Each fiscal year is based on the fiscal year of each Group company. Point-in-time metrics are reported as of each Group company's fiscal year-end, while period metrics reflect results for each Group company's fiscal year.

◆ Employee composition and diversity

Number of employees

Unit: persons

item	classification	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Number of employees (regular employees ^*1)		Consolidated	6,866	7,176	7,259	9,144	9,292
Number of employees by region	Japan	Consolidated	2,652	2,784	2,866	2,922	2,946
	Asia	Consolidated	3,324	3,500	3,483	5,119	5,214
	Americas ^*2	Consolidated	472	471	484	512	551
	Europe ^*2	Consolidated	374	375	376	530	520
	Oceania	Consolidated	44	46	50	61	61
Number of employees by gender	men	Consolidated	2,890	3,042	3,117	3,686	3,749
Number of employees by gender	woman	Consolidated	3,976	4,134	4,142	5,458	5,543

*1 Excludes fixed-term employees, part-time employees, and company officers.

*2 The Americas include Central and South America; Europe includes the Middle East and Africa.

Percentage of employees by age group

unit:%

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Under 30 years old	Consolidated	22.1	22.4	21.7	21.0	20.8
30-49 years old	Consolidated	62.6	61.4	61.1	59.5	59.4
50 years old and over	Consolidated	15.2	16.3	17.2	19.5	19.8

Women's empowerment

unit:%

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Share of women in total workforce	Consolidated	57.9	57.6	57.1	59.7	59.7
Share of women in management positions	Consolidated	35.5	36.0	36.7	39.1	40.8
Share of women in management positions	Rohto Pharmaceutical	26.0	30.0	32.8	30.0	31.0
Share of women in senior management positions^*1	Consolidated	32.4	34.3	31.0	34.1	40.7
Share of women in middle management positions^*1	Consolidated	45.1	45.7	44.3	38.7	39.9
Share of women in junior management positions^*1	Consolidated	35.2	35.6	37.7	39.9	41.1
Share of women in management positions in revenue-generating functions ^*2	Consolidated	39.4	40.5	41.0	42.3	44.9
Share of women in STEM-related positions ^*3	Consolidated	52.9	52.8	51.7	51.0	49.9

*1 Senior, middle, and junior management positions are classified based on Group-wide criteria for responsibilities and authority.

*2 Functions directly involved in revenue generation, such as the creation and delivery of products and services and business development. Administrative and support functions are excluded.

*3 Positions requiring expertise related to science, technology, engineering, or mathematics (STEM), in which such knowledge and skills are applied in the course of work.

Average length of service

unit: year

item	classification	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Average length of service	men	Rohto Pharmaceutical	15.0	15.3	14.9	14.4	13.9
	woman	Rohto Pharmaceutical	12.8	13.1	13.6	13.7	13.6
	total	Rohto Pharmaceutical	13.6	14.0	14.1	14.0	13.8

Average age

Unit: years old

item	classification	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Average age	men	Rohto Pharmaceutical	41.8	42.6	42.3	41.9	41.5
	woman	Rohto Pharmaceutical	41.4	41.8	42.3	42.8	42.6
	total	Rohto Pharmaceutical	41.5	42.0	42.3	42.3	42.1

Employment of persons with disabilities

unit:%

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Employment rate of persons with disabilities^*1	4 major companies in Japan^*2	－	－	－	－	2.8
Employment rate of persons with disabilities^*1	Rohto Pharmaceutical	2.4	2.3	2.5	2.6	3.0

*1 Calculated in accordance with the methodology prescribed under Japan's Act to Facilitate the Employment of Persons with Disabilities.

*2 The four major companies in Japan are ROHTO Pharmaceutical Co., Ltd., Qualitech Pharma Co., Ltd., ROHTO NITTEN Co., Ltd., and Amato Pharmaceutical Products, Ltd. Together, they account for at least 90% of the total number of employees in Japan (as of March 2026).

◆ Recruitment and employee turnover

New employee hires

Units: persons / %

item	classification	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Number of new employee hires	men	Rohto Pharmaceutical	18 45.0%	17 36.2%	55 59.1%	37 49.3%	29 48.3%
	woman	Rohto Pharmaceutical	22 55.0%	30 63.8%	38 40.9%	38 50.7%	31 51.7%
	total	Rohto Pharmaceutical	40 100.0%	47 100.0%	93 100.0%	75 100.0%	60 100.0%
Number of new graduate hired	men	Rohto Pharmaceutical	10 38.5%	8 29.6%	18 51.4%	23 46.9%	21 45.7%
	woman	Rohto Pharmaceutical	16 61.5%	19 70.4%	17 48.6%	26 53.1%	25 54.3%
	total	Rohto Pharmaceutical	26 100.0%	27 100.0%	35 100.0%	49 100.0%	46 100.0%
Number of mid-career hires*	men	Rohto Pharmaceutical	8 57.1%	9 45.0%	37 63.8%	14 53.8%	8 57.1%
	woman	Rohto Pharmaceutical	6 42.9%	11 55.0%	21 36.2%	12 46.2%	6 42.9%
	total	Rohto Pharmaceutical	14 100.0%	20 100.0%	58 100.0%	26 100.0%	14 100.0%

*Includes rehires

Employee turnover rates

unit:%

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Voluntary employee turnover rate ^*1	Consolidated	13.2	12.6	12.4	12.2	14.9
Voluntary employee turnover rate ^*1	Rohto Pharmaceutical	2.2	3.1	1.7	1.4	2.1
Total employee turnover rate	Consolidated	14.4	13.3	13.1	13.0	16.2
Total employee turnover rate	Rohto Pharmaceutical	2.4	3.1	2.0	1.5	2.4

* Voluntary turnover excludes mandatory retirement, death in service, and employer-initiated separations. For ROHTO Pharmaceutical, the definition was revised from FY2025 to align with the consolidated basis.

◆ Compensation

Average annual salary of employees

item	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Average annual salary	Rohto Pharmaceutical	thousand yen	7,566	7,819	8,176	8,261	8,505
Year-on-year change in average annual salary	Rohto Pharmaceutical	%	－	－	－	－	2.9
Ratio of women's pay to men's pay (all employee) *	Rohto Pharmaceutical	%	－	60.6	62.1	65.8	67.8

* The ratio represents women's pay as a percentage of men's pay.

There are no gender-based differences in pay structures or compensation systems. The difference is mainly attributable to factors such as differences in length of service and representation in higher job grades between men and women.

◆ Workstyle and work -life balance support

Utilization of childcare support programs

item	classification	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Parental leave uptake rate	men	4 major companies in Japan	%	－	－	－	88.7	91.4
	men	Rohto Pharmaceutical	%	22.2	26.5	46.4	97.5	92.3
	woman	Rohto Pharmaceutical	%	100.0	97.6	100.0	100.0	100.0
Number of employees using reduced working hours for childcare*	men	Rohto Pharmaceutical		0	1	1	6	3
	woman	Rohto Pharmaceutical		128	103	135	143	144

*Number of regular employees who have continuously worked reduced hours for childcare for at least one month. Temporary arrangements lasting less than one month are excluded.

Overtime work and annual paid leave

item	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Overtime work per employee	4 major companies in Japan	hours / month	－	－	－	－	11.7
Overtime work per employee	Rohto Pharmaceutical	hours / month	14.7	14.9	13.3	12.3	11.7
Annual paid leave utilization rate	4 major companies in Japan	％	－	－	－	－	80.6
Annual paid leave utilization rate	Rohto Pharmaceutical	％	68.6	72.9	80.0	76.9	80.5
Percentage of employees taking 5 or more consecutive days of leave	Rohto Pharmaceutical	％	41.7	35.1	36.9	34.5	37.8

◆ Human capital development, career, and well-being

Human capital development

item	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Average training hours per employee	Rohto Pharmaceutical	hours / year	7	34	37	49	27
Average training expenditure per employee	Rohto Pharmaceutical	thousand yen	81	83	101	110	110

Internal double jobs and external challenge work

Unit: persons

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Number of employees participating in Internal Double jobs	Rohto Pharmaceutical	123	123	192	207	233
Number of employees engaged in External Challenge Work	Rohto Pharmaceutical	52	49	61	65	76

Well-being survey score (engagement)

Unit: points

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Average score across five items*	Rohto Pharmaceutical	－	6.84	6.89	6.98	6.99

* Annual average score based on employees' self-assessment of their well-being, with each item rated on a 10-point scale.

◆ Health and productivity management

Health indicators (health KPIs)

classification	item	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Outcome indicators (physical health)	Percentage of employees with or at risk of metabolic syndrome	Rohto Pharmaceutical	％	14.1	14.8 （6.1＋8.7）	14.2 （6.1＋8.1）	15.4 （5.9＋9.5）	14.9 （6.5＋8.4）
	Percentage of women with anemia*1	Rohto Pharmaceutical	％	14.8	14.2	15.9	14.5	14.5
	Percentage of employees whose kenryoku Age is lower than their actual age^*2	Rohto Pharmaceutical	％	－	62.6	67.3	67.2	64.0
Behavioral indicators (lifestyle)	Percentage of employees who smoke	Rohto Pharmaceutical	％	1.9	2.8	2.2	2.6	2.0
	Percentage of employees whose alcohol consumption is within the recommended limit^*3	Rohto Pharmaceutical	％	74.2	76.9	76.5	77.2	76.5
	Percentage of emploees satisfied with their Sleep^*4 (employees sleeping at least six hours)	Rohto Pharmaceutical	％	－	34.5 （58.6）	47.9 （58.5）	47.5 （55.9）	49.9 （56.6）
	Percentage pf employees engaging in at least 30 minutes of exercise at least twice a week	Rohto Pharmaceutical	％	39.0	38.3	41.4	43.1	44.2
	Percentage of employees achieving 8,000 steps and 20 minutes of brisk walking per day	Rohto Pharmaceutical	％	14.9 （52.3^※5）	16.5 （54.9^※5）	15.2 （43.4^※5）	11.7 （46.5^※5）	11.8 （48.8^※5）
Fulfillment indicators (mindset)	Percentage of employees sending 39 (Thank You) Messages ^*6 (percentage receiving messages)	Rohto Pharmaceutical	％	－	67.9 （89.6）	69.5 （89.2）	68.9 （90.0）	68.4 （90.3）
	Percentage of employees putting learning into practice	Rohto Pharmaceutical	％	－	－	－	62.4	61.2
	Overtime hours per employee	Rohto Pharmaceutical	hours / month	14.7	14.9	13.3	12.3	11.7
	Percentage of employees taking 5 or more consecutive days of leave	Rohto Pharmaceutical	％	41.7	35.1	36.9	34.5	37.8

*1 Anemia is defined as a hemoglobin level of less than 12.0 g/dL.

*2 Kenryoku Age < Actual Age is defined as cases where at least two of the three physical fitness assessment results—fitness age, walking age, and Brain Fitness®—are lower than the employee's actual age.

*3 The recommended alcohol consumption limit is defined as less than two go (a Japanese sake-equivalent unit) per occasion for men and less than one go per occasion for women.

*4 Percentage of respondents who selected “very satisfied” or “somewhat satisfied” on a four-point scale. In FY2022, a five-point scale including a neutral response option was used.

*5 Average over the period during which the event was held.

*6 An internal messaging tool that allows employees to express their gratitude to one another.

Health checkups and stress checks

unit:%

item	Scope	FY2021	FY2022	FY2023	FY2024	FY2025
Health checkup participation rate	4 major companies in Japan	－	－	－	－	100
Health checkup participation rate	Rohto Pharmaceutical	－	100	100	100	100
Stress check participation rate	Rohto Pharmaceutical	－	94.6	98.8	99.8	99.8

◆ Occupational health and safety

Work-related injuries ^*1

item	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Serious work-related injuries and illnesses ^*2	Consolidated	cases	0	0	0	0	0
Lost time injuries: 4 or more lost workdays ^*3	Consolidated	cases	13	19	18	23	17
Lost-time-injuries: 1-3 lost workdays	Consolidated	cases	6	14	12	28	7
Non-lost-time injuries	Consolidated	cases	13	26	34	18	43
Lost-time injury frequency rate （LTIFR）^*4	Consolidated	－	1.31	2.24	2.00	2.66	1.23

*1 The reporting scope comprises the companies consolidated in each fiscal year. Newly consolidated companies are included from the fiscal year in which they enter the scope of consolidation, and prior-year data are not retrospectively restated.

The reporting scope expanded significantly from FY2024 with the addition of Eu Yan Sang International Ltd, MoNo chem-pharm Produkte GmbH, Sigmapharm Arzneimittel GmbH, and other companies.

*2 Serious work-related injuries and illnesses resulting in death or permanent impairment.

*3 The scope of lost-time and non-lost-time injuries is based on the reporting criteria of each Group company in accordance with applicable laws and regulations in each country or region.

*4 The lost-time injury frequency rate (LTIFR) is calculated as the number of work-related injuries resulting in one or more lost workdays divided by total hours worked, multiplied by 1,000,000.

◆ Labor-management relations

Labor-management relations

item	Scope	unit	FY2021	FY2022	FY2023	FY2024	FY2025
Number of labor union members	Rohto Pharmaceutical		1,476	1,498	1,612	1,690	1,707
Labor union membership rate	Rohto Pharmaceutical	％	92.2	92.3	92.0	95.6	95.6

Governance

Reporting Period: Calculated at the end of each fiscal year.

◆ Corporate Governance

Board of Directors and Board of Auditors Composition

Units: persons, years

		FY2021	FY2022	FY2023	FY2024	FY2025	As of August 2026
Board of directors	total	9	11	11	13	14	14
	Outside Director	3 33.3%	4 36.4%	4 36.4%	5 38.5%	5 35.7%	5 35.7%
	Female Director	2 22.2%	3 27.3%	3 27.3%	4 30.8%	6 42.9%	6 42.9%
	Average length of service	7.1	6	6.5	6.2	6.1	7.1
Board of Auditors	total	4	4	4	4	5	5
	Outside Audit & Supervisory Board Member	2 50.0%	2 50.0%	2 50.0%	2 50.0%	3 60.0%	3 60.0%
	Female auditor	0 0%	0 0%	0 0%	1 25.0%	2 40.0%	2 40.0%

*As of March 31st of each fiscal year. However, the average length of service is as of the end of June. Note that past terms of service as a director are not included if the director was reappointed after stepping down.

Activity Status

		FY2022	FY2023	FY2024	FY2025
Board of directors	Number of times held	8	8	8	8
Board of directors	Average attendance rate*	99.1%	99.2%	97.8%	100%
Nomination committee	Number of times held	3	4	3	3
Nomination committee	Average attendance rate	100%	100%	100%	100%
Compensation committee	Number of times held	4	4	3	3
Compensation committee	Average attendance rate	100%	100%	100%	100%
Board of Auditors	Number of times held	28	17	18	18
Board of Auditors	Attendance rate	100%	100%	98.6%	100%

*Includes directors and auditors

Executive Compensation Status

Units: million yen, people

			FY2021	FY2022	FY2023	FY2024	FY2025
Directors (Excluding outside directors)	Total amount of compensation, etc.		393	441	445	496	539
	Rewards, etc. Total amount by type	Fixed Compensation	353	391	395	446	473
	Rewards, etc. Total amount by type	Performance-linked Compensation	40	50	50	50	66
	Number of officers subject to the requirement		6	7	9	9	10
Auditor (Excluding Outside Audit & Supervisory Board Member)	Total amount of compensation, etc.		39	40	41	42	43
	Rewards, etc. Total amount by type	Fixed Compensation	39	40	41	42	43
	Rewards, etc. Total amount by type	Performance-linked Compensation	－	－	－	－	－
	Number of officers subject to the requirement		2	2	2	2	2
Outside Director	Total amount of compensation, etc.		40	46	51	61	73
	Rewards, etc. Total amount by type	Fixed Compensation	40	46	51	61	73
	Rewards, etc. Total amount by type	Performance-linked Compensation	－	－	－	－	－
	Number of officers subject to the requirement		5	7	6	7	9

◆ Risk Management

Supplier CSR Assessment

	FY2021	FY2022	FY2023	FY2024	FY2025
Number of suppliers	－	－	44	70	－
Response rate	－	－	100%	100%	－
Percentage of total procurement value among Tier-1 suppliers	－	－	80%	90%	－

*Regular surveys will be conducted every two years starting in fiscal year 2024.

◆ Compliance

Hotline Reports and Consultations

Unit: cases

	FY2024			FY2025
	Japan	Outside Japan	total	Japan	Outside Japan	total
Discrimination / Harassment	5	6	11	12	0	12
Workplace Environment / Communication	12	3	15	20	4	24
Labor Management	5	1	6	2	3	5
Proper Business Conduct	2	0	2	2	0	2
Morality	4	0	4	1	0	1
Suspected Misconduct	4	2	6	2	4	6
Others	0	0	0	2	1	3
total	32	12	44	41	12	53

Number of Violations

Unit: cases

	FY2024	FY2025
	Japan	Japan	Outside Japan	total
Corruption or Bribery	0	0	0	0
Leakage of Customer Personal Information	0	0	0	0
Conflict of Interest Transactions	0	0	0	0
Money laundering or insider trading	0	0	0	0
Dismissal for Disciplinary Reasons	0	0	1	1
Others	1^*1	0	1^*2	1